دورية أكاديمية
Association between Levocarnitine Treatment and the Change in Knee Extensor Strength in Patients Undergoing Hemodialysis: A Post-Hoc Analysis of the Osaka Dialysis Complication Study (ODCS)
| العنوان: | Association between Levocarnitine Treatment and the Change in Knee Extensor Strength in Patients Undergoing Hemodialysis: A Post-Hoc Analysis of the Osaka Dialysis Complication Study (ODCS) |
|---|---|
| المؤلفون: | Shota Matsufuji, Tetsuo Shoji, Suhye Lee, Masao Yamaguchi, Mari Nishimura, Yoshihiro Tsujimoto, Shinya Nakatani, Tomoaki Morioka, Katsuhito Mori, Masanori Emoto |
| المصدر: | Nutrients, Vol 14, Iss 2, p 343 (2022) |
| بيانات النشر: | MDPI AG, 2022. |
| سنة النشر: | 2022 |
| المجموعة: | LCC:Nutrition. Foods and food supply |
| مصطلحات موضوعية: | muscle strength, hemodialysis, carnitine deficiency, sarcopenia, frailty, Nutrition. Foods and food supply, TX341-641 |
| الوصف: | Carnitine deficiency is prevalent in patients undergoing hemodialysis, and it could result in lowered muscle strength. So far, the effect of treatment with levocarnitine on lower limb muscle strength has not been well described. This observational study examined the association between treatment with levocarnitine with the change in knee extensor strength (KES) in hemodialysis patients. Eligible patients were selected from the participants enrolled in a prospective cohort study for whom muscle strength was measured annually. We identified 104 eligible patients for this analysis. During the one-year period between 2014 to 2015, 67 patients were treated with intravenous levocarnitine (1000 mg per shot, thrice weekly), whereas 37 patients were not. The change in KES was significantly higher (p = 0.01) in the carnitine group [0.02 (0.01–0.04) kgf/kg] as compared to the non-carnitine group [−0.02 (−0.04 to 0.01) kgf/kg]. Multivariable-adjusted regression analysis showed the positive association between the change in KES and the treatment with levocarnitine remained significant after adjustment for the baseline KES and other potential confounders. Thus, treatment with intravenous levocarnitine was independently and positively associated with the change in KES among hemodialysis patients. Further clinical trials are needed to provide more solid evidence. |
| نوع الوثيقة: | article |
| وصف الملف: | electronic resource |
| اللغة: | English |
| تدمد: | 14020343 2072-6643 |
| العلاقة: | https://www.mdpi.com/2072-6643/14/2/343Test; https://doaj.org/toc/2072-6643Test |
| DOI: | 10.3390/nu14020343 |
| الوصول الحر: | https://doaj.org/article/cf2ea5e9d2614e619d350e372954173dTest |
| رقم الانضمام: | edsdoj.f2ea5e9d2614e619d350e372954173d |
| قاعدة البيانات: | Directory of Open Access Journals |
Full Text Finder | تدمد: | 14020343 20726643 |
|---|---|
| DOI: | 10.3390/nu14020343 |